Ruth Vera

List of Publications by Year
in descending order

30 papers	1,095 citations	566801 15 h-index	476904 29 g-index
35 all docs	35 docs citations	35 times ranked	1725 citing authors

#	Article	IF	Citations
1	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports, 2017, 20, 1818-1829.	2.9	220
2	Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> â€L1/<scp>PD</scp> â€1 blockade therapy. EMBO Molecular Medicine, 2019, 11, e10293.	3.3	145
3	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Annals of Oncology, 2013, 24, 2342-2349.	0.6	89
4	Understanding LAG-3 Signaling. International Journal of Molecular Sciences, 2021, 22, 5282.	1.8	78
5	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 2020, 12, 344.	1.7	60
6	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 1631.	1.8	59
7	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. Frontiers in Pharmacology, 2020, 11, 441.	1.6	48
8	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clinical and Translational Oncology, 2019, 21, 46-54.	1.2	40
9	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. Frontiers in Immunology, 2020, 11, 586907.	2.2	40
10	Clinical landscape of LAG-3-targeted therapy. Immuno-Oncology Technology, 2022, 14, 100079.	0.2	37
11	LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Annals of Oncology, 2020, 31, S242-S243.	0.6	31
12	First-line bevacizumab and capecitabineâ€"oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. British Journal of Cancer, 2014, 111, 241-248.	2.9	29
13	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 823-834.	1.2	29
14	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. International Journal of Molecular Sciences, 2020, 21, 2411.	1.8	28
15	Systemic CD4 immunity: A powerful clinical biomarker for PDâ€L1/PDâ€1 immunotherapy. EMBO Molecular Medicine, 2020, 12, e12706.	3.3	19
16	Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. Clinical and Translational Oncology, 2014, 16, 739-745.	1.2	18
17	Hyperprogressive Disease: Main Features and Key Controversies. International Journal of Molecular Sciences, 2021, 22, 3736.	1.8	18
18	Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Clinical and Translational Oncology, 2017, 19, 498-507.	1.2	15

#	ARTICLE	IF	CITATIONS
19	Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. International Journal of Colorectal Disease, 2020, 35, 739-746.	1.0	12
20	Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. Clinical and Translational Oncology, 2022, 24, 112-126.	1.2	12
21	Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. Cancers, 2020, 12, 2181.	1.7	9
22	Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. Clinical and Translational Oncology, 2020, 22, 2253-2263.	1.2	9
23	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. British Journal of Cancer, 2022, 126, 1168-1177.	2.9	9
24	CAR-T Cells for the Treatment of Lung Cancer. Life, 2022, 12, 561.	1.1	8
25	Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. Cancers, 2020, 12, 2259.	1.7	6
26	Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clinical and Translational Oncology, 2021, 23, 1520-1528.	1.2	4
27	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clinical and Translational Oncology, 2022, 24, 968-980.	1.2	3
28	The Determination of a Consensus Nutritional Approach for Cancer Patients in Spain Using the Delphi Methodology. Nutrients, 2022, 14, 1404.	1.7	3
29	Future care for long-term cancer survivors: towards a new model. Clinical and Translational Oncology, 2022, 24, 350-362.	1.2	2
30	TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology, 2020, 22, 1423-1424.	1.2	0